How can we optimize erythropoetic therapy in patients with anemia of chronic kidney disease? How widespread is the problem of hyporesponsiveness to erythropoetic-stimulating agents? Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey, joins host Dr. Charles Turck.